000			03662nam a2200337 i 4500
999			_c399021 _d399021
001			399021
003			ES-MaUEC
005			20240318150212.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			230808s2023 sz | o |||| 0|eng d
020			_a9783031351556
024	7		_a10.1007/978-3-031-35155-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRS164 _b2023 EB
100	1		_aRoss, Ivan A. _eautor _4aut _4http://id.loc.gov/vocabulary/relators/aut _9689862
245	1	0	_aPlant-Based Therapeutics _b _nVolume 1, _pCannabis sativa _cby Ivan A. Ross
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
505	0		_aChapter 1 The History of Cannabis -- Chapter 2 The Bioactive Components of Plants -- Chapter 3 Chemical Constituents of Cannabis -- Chapter 4 The Bioactive Components of Cannabis -- Chapter 5 Neurological Effects of Cannabis -- Chapter 6 Psychotropic Effects of Cannabis -- Chapter 7 The Analgesic effects of Cannabis -- Chapter 8 Cannabis and Perinatal Development -- Chapter 9 Cannabis and Multiple Sclerosis -- Chapter 10 Cannabis and Cancer -- Chapter 11 Cannabis and Parkinson's disease -- Chapter 12 Cannabis and the Skin -- Chapter 13 Antiviral Activities of Cannabis -- Chapter 14 Alkaline Phosphatase Stimulation.
520			_aBy examining historical applications of the compounds found in plants, this five-volume series serves as a reference for quality assurance, research, product development, and regulatory guidance of the compounds found in plant-based medicines. This work supports the growing consumers' interest in herbal medicine for wellness and health. Plant-Based Therapeutics, Volume 1: Cannabis sativa, the first in the series, covers a unique plant species and provides the framework to integrate its evidence-based scientific discoveries with healthcare therapies. Cannabis has been used in religious ceremonies and medical purposes for thousands of years. Cannabidiol (CBD), the main non-psychoactive component of Cannabis, was isolated in the 1940s, and its structure was established in the 1960s. In 1964 tetrahydrocannabinol (THC), the psychoactive component, was isolated. Cannabis has more than 500 components, of which 104 cannabinoids have been identified. Two of them, THC and CBD, have been the primary components of scientific investigations. They were approved by the FDA for chemotherapy-induced nausea and vomiting in 1985; for appetite stimulation in wasting conditions, such as AIDS, in 1992, and in 2018 for treating two forms of pediatric epilepsy, Dravet syndrome and Lennox-Gastaut syndrome. Beyond the indications for which cannabinoids are FDA-approved, the evidence reveals that cannabinoid receptors are present throughout the body, embedded in cell membranes, and are believed to be more numerous than any other receptor system. When cannabinoid receptors are stimulated, a variety of physiologic processes ensue. Thus, other constituents of Cannabis are extremely promising either as individual compounds or their potential synergistic or entourage effects in the treatment of numerous medical conditions. .
988			_aSpringer_BiomedLife_2023
650		7	_2embne _9404971 _aPlantas medicinales
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-35155-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b03/2024 _dz _eb _zSI